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Tumor hypoxia is an adverse factor for chemotherapy and radiotherapy. Ozone therapy is a non-
conventional form of medicine that has been used successfully in the treatment of ischemic disorders.
This prospective study was designed to assess the effect of ozone therapy on tumor oxygenation.
Eighteen subjects were recruited for the study. Systemic ozone therapy was administered by auto-
hemotransfusion on three alternate days over one week. Tumor oxygenation levels were measured
using polarographic needle probes before and after the first and the third ozone therapy session.
Overall, no statistically significant change was observed in the tumor oxygenation in the 18 patients.
However, a significant decrease was observed in hypoxic values ≤10 and ≤5 mmHg of pO2. When
individually assessed, a significant and inverse non-linear correlation was observed between increase
in oxygenation and the initial tumor pO2 values at each measuring time-point, thus indicating that
the more poorly-oxygenated tumors benefited most (rho = –0.725; P = 0.001). Additionally, the
effect of ozone therapy was found to be lower in patients with higher hemoglobin concentrations
(rho = –0.531; P < 0.034). Despite being administered over a very short period, ozone therapy im-
proved oxygenation in the most hypoxic tumors. Ozone therapy as adjuvant in chemo-radiotherapy
warrants further research.
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Introduction
Tumor hypoxia can cause an increase in radio-resistance by
up to 2.5–3 times (1) and predisposes a physiologic selection
of tumor cells with decreased apoptosis. This results in addi-
tional resistance to radiotherapy and chemotherapy (2) and
further increase in angiogenesis and a more aggressive tumor
potential (3–5).
Tumor hypoxia, when assessed by polarographic probes, is
an independent prognostic factor for response to treatment
and/or survival of head and neck tumors (6–9) and uterine
cervical tumors (10,11) as well as sarcomas (12,13). The
polarographic probe technique was designated as ‘gold
standard’ for tumor pO2 measurement in a special workshop
sponsored by the National Cancer Institute (14), at which the
importance of developing methods to overcome tumor
hypoxia was emphasized. Since then, meta-analyses have
demonstrated that hypoxia modification during radiotherapy
can improve treatment outcomes (15).
Ozone therapy has been shown to be beneficial to patients
with ischemic disorders, particularly of the lower limbs (16–
18). In our previous studies we had found that ozone therapy
increases oxygenation in the most poorly-oxygenated tissues
of the anterior tibialis muscles (19) and that oxygenation in
these muscles might be related to tumor oxygenation (20).
The objective of the present preliminary (and prospective)
study is to evaluate the effect of ozone therapy on tumor
oxygenation, using the polarographic probe measurement
technique.
Subjects and Methods
Patients
Eighteen patients with accessible metastases or advanced
tumors were enrolled in the study (14 with head and neck
tumors, 2 with gynecological tumors and two bone metas-
tases in chest wall region). Patients comprised 15 males and 3
females with mean age of 64 years (range, 50–91). The selec-
tion criteria included the following: a minimum age of 1894 Effect of ozone on tumor oxygenation
years, Karnofsky performance status of >70%, cancer diag-
nosis histologically confirmed with metastases or advanced
tumors accessible to physical examination and not being suit-
able for surgical resection. The mean of measured tumors/
nodes was 6.5 cm across the greatest diameter (range, 3–12
cm). The exclusion criteria included the following: unwilling-
ness to participate in the study, treatment with experimental
or evaluation drugs during the planned study or not fulfilling
all of the selection criteria described above. The experimental
nature of the study was explained in detail and informed con-
sent was obtained from all patients prior to study. The study
was approved by the Institutional Ethical Committee.
Ozone Therapy
Ozone therapy was administered by autohemotransfusion on
three alternate days over one week. The procedure involved
the extraction of 200 ml venous blood into heparin (25 IU/
ml) and CaCl2 (5mM). Using clinical-grade O2, the O3/O2 gas
mixture was prepared with an OZON 2000 device (Zotzmann
+ Stahl GmbH, Plüderhausen, Germany) and sterilized by
passing it through a sterile 0.20-µm filter. The blood was
mixed with 200 ml of the O3/O2 gas mixture at a concentra-
tion of 60 µg/ml, in a single-use sterile container with a
capacity of 300 ml. Following this, it was slowly re-introduced
into the patient’s body. The blood had been extra-corporeal
for about 15–30 minutes but no adverse reactions were
observed. Table 1 summarizes some of the most relevant
clinical characteristics of the patients.
Tumor pO2 Measurement
Tumor oxygenation was measured using a polarographic
probe system: the ‘pO2 Histograph’ (Eppendorf AG, Ham-
burg, Germany). The details of this technique have been
described previously (21). Briefly, a 0.5 mm diameter elec-
trode (0.3 mm diameter at the tip) is inserted into the tumor
while the patient is under subcutaneous anesthesia. The
movement is computer controlled and consists of a 1 mm
forward motion and a 0.3 mm backward motion to avoid
tissue compression at the measurement site. A pO2 value is
obtained at every 0.7 mm. For each set of measurements
obtained, 150–200 single pO2 values were automatically
recorded using at least six different electrode tracks. To deter-
mine tumor oxygenation, median pO2 and the percentage of
pO2 values ≤10 mmHg and ≤5 mmHg were obtained from the
pooled data for each individual.
Tumor oxygenation values were obtained on four occa-
sions: First, before session #1; second, after session #1; third,
48 h after session #2 and before session #3; fourth, after
session #3.
For each tumor, the change in oxygenation (∆pO2) was
calculated as the pO2 value at each time-point relative to the
pre-session #1 (‘baseline’) pO2 value.
The measurements were carried out on accessible, clinically
palpable lymph nodes or subcutaneous metastases without
using an imaging technique.
Table 1. Characteristics of the patients and their tumors
Stage; T = Tumor; N = Node: according to AJCC cancer staging manual, 5th edition. Size = largest diameter clinically measured (in cm). All pO2 measure-
ments were in the largest node. UPT = unknown primary tumor. pO2 pre-1 = pO2 before session #1 = basal. pO2 post-1 = pO2 after session #1. pO2 pre-3 =
pO2 48 h after session #2 and before session #3. pO2 post-3 = pO2 after session 3. N.A. = not available.
Patient Age Location Stage Size Hb pO2 pre-1 pO2 post-1 pO2 pre-3 PO2 post-3
1 70 Maxillary bone relapsed chondrosarcoma 4 * 4 13.4 1 N.A. 33.9 21.9
2 60 Vulva, relapsed NA 36 47.3 11.5 11.9
3 56 Tongue T4 N2c M0 4 * 2 13.5 70 68.7 76.7 65.3
4 63 Hypopharynx T4 N2a M0 5.5 * 5.5 12.1 17 N.A. 29.0 29.5
5 91 Hodgkin disease II-A 9 * 6 10.8 3 9.1 18.1 9.7
6 51 Thyroid Medullar carcinoma T4 N1 M1 10 * 7 13.4 29 38.8 31.5 34.1
7 52 Nasopharynx T4 N2c M0 5 * 5 15.6 64 56.3 48.3 45.7
8 50 Vagina T3 N0 M0 13.2 2 4.7 24.2 19.3
9 60 Oropharynx, relapsed 3 * 3 14.0 38 39.6 39.0 32.0
10 76 Chest wall metastases clear cell carcinoma Tx Nx M1 6 * 6 13.3 43 48.5 39.6 18.9
11 69 Chest wall metastases hepatocellular carcinoma T3 N0 M1 10 * 8 NA 29 42.9 34.4 34.0
12 65 Oesophagus, relapsed 3 * 3 10.8 1 31.8 3.1 30.9
13 68 Hypopharynx T3 N2b M1 3 * 3 11.8 38 47.3 35.9 27.1
14 53 Hypopharynx T4 N3 M1 12 * 10 11.7 15 38.0 31.1 45.0
15 74 Oropharynx T4 N2c M0 5 * 3.5 15.3 7 8.6 12.0 6.8
16 63 Supraglottis T2 N3 M0 8.5 * 5.5 13.6 3 9.9 13.2 4.3
17 67 Oral cavity T4 N3 M0 8.5 * 5.5 14.7 1 2.2 1.3 .9
18 71 Cervical metastases from UPT Tx N3 M1 12 * 7.5 15.6 17 17.1 9.0 13.9eCAM 2004;1(1) 95
Statistical Analysis
The SPSS 11.0 for Windows software package was used for
this study. The distribution of data was assessed by the
Kolgomorov–Smirnov test. Two-tailed tests were applied for
significance. The paired t-test was used to compare means of
all the median tumor values and all the percentages of the
≤10 and ≤5 mmHg measurements. These data are expressed
as means ± SD. The Mann–Whitney U test was used to com-
pare the ∆pO2 between tumors above and below the median
baseline pO2. These data are expressed as median and 25%-
75% inter-quartile interval. Linear correlation was assessed
by Pearson’s r test and non-linear correlation by Spearman’s
rho test. Differences were considered significant at the P <
0.05 level.
Results
Tumor Oxygenation
The patient’s individual data for hemoglobin levels and pO2
values at each measurement time-point are shown in Table 1.
Initial tumor oxygenation was 23 ± 5.1 mmHg, and was not
related to sex, age, hemoglobin levels, clinical status or tumor
size.
After session #1 tumor oxygenation was 31.9 ± 5.1 mmHg,
and this difference was significant, P = 0.009. However, no
statistically significant differences were found in the other
two measurement time-point: 48 h after session #2 (27.3 ±
4.3 mmHg) and after session 3 (25.1 ± 3.9 mmHg).
Hypoxic Values
The percentage of values ≤10 mmHg at the baseline pro-
ceeded to decrease significantly during ozone therapy from
40.8 ± 7.3% to 27.4 ± 7.3% (P = 0.002) after session #1 and
to 29 ± 6.2% (P = 0.039) 48 h after session #2. The decrease
to 31 ± 5.1% after session #3 did not qualify as statistical
significance (P = 0.058).
The percentage of values ≤5 mmHg at the baseline pro-
ceeded to decrease significantly during ozone therapy from
34.8 ± 7.5% to 21.7 ± 6.9% (P = 0.002) after session #1, to
23.8 ± 5.9% (P = 0.045) 48 h after session 2 and to 23.9 ±
4.9% (P = 0.033) after session #3 (Fig. 1).
Factor of Change of pO2 (∆pO2):
At each measurement time-point, an inverse and non-linear
correlation was found between individual ∆pO2 and initial
pO2 values. A higher ∆pO2 was observed in those tumors that
had had lower initial pO2 values. Significant changes were
observed after session #1 (rho = –0.812, P < 0.001), 48 h
after session #2 (rho = –0.798, P < 0.001) and after session
#3 (rho = –0.725, P = 0.001) (Fig. 2).
This was corroborated by the comparison of ∆pO2 between
tumors above and below the median pO2 prior to ozone
therapy (baseline), at each measurement time-point. While
the initially well-oxygenated tumors (those above the median)
showed oxygenation decrease, the initially most poorly-
oxygenated tumors (those below the median) showed an in-
crease in oxygenation after the ozone therapy. The changes
recorded were a factor of 2.5 (range, 2–3.1; P = 0.002) after
session #1, a factor of 4.1 (range, 1.7–8; P < 0.001) 48 h after
session #2, and a factor of 2.9 (range, 1.1–15; P = 0.002)
after session #3 (Fig. 3).
Further, at each measurement time-point, an inverse, non-
linear correlation between individual ∆pO2 and hemoglobin
levels was found. The ∆pO2 in tumors was lower in patients
with higher hemoglobin levels after session #1 (rho = –0.650,
Figure 1. Change in percentage of pO2 values ≤5 mmHg. During ozone ther-
apy, a decrease in percentage of pO2 values ≤5 mmHg at each measurement
time-point was observed in the tumors of patients: Baseline = before ozone
therapy; post-1 = after session #1 (P = 0.002); 48 post-2 = 48 h after
session #2 (P = 0.045); post-3 = after session #3 (P = 0.033). Significant
differences (P < 0.05) are indicated with an asterisk (*)
Figure 2. Factor of change in pO2 (∆pO2) and initial pO2 For each partici-
pant, the ∆pO2 was calculated as the pO2 value at each time-point relative to
the baseline pO2 value measured before the start of the ozone therapy. A
non-linear correlation was found between baseline pO2 and ∆pO2 at each
measurement time-point. The figure shows an inverse correlation (rho =
–0.798) after session #3 of ozone therapy, which indicates that the highest
therapy-associated changes in tumor pO2 occurred in tumors with the poor-
est baseline oxygenation. A ∆pO2 value <1 signifies decrease in oxygenation
and ∆pO2 >1 signifies an increase in tumor oxygenation after session #3.96 Effect of ozone on tumor oxygenation
P = 0.012), 48 h after session #2 (rho = –0.531, P = 0.034)
and after session #3 (rho = –0.579, P = 0.019) (Fig. 4).
Discussion
Ozone (O3) is the allotropic form of oxygen with three atoms
and two unpaired electrons, which has a higher oxidizing
capacity than oxygen. In order to avoid lung toxicity, medical
applications of ozone require to preclude airways involve-
ment. Autohemotransfusion fulfils this requirement. In
appropriate concentrations, this technique leads to a tran-
sient oxidative stress that can stimulate blood antioxidants by
up-regulation (22–24). This mechanism has been ascribed to
ozone therapy’s protection against free radical damage of
heart (22), and prevention of renal (25) and hepatic (26) dis-
orders. Hemolysis of <2.5% and an acceptable level of lipid
peroxide formation has been described in autohemotrans-
fusion at O3/O2 concentrations of 60 µg/ml (23).
The objective of the present study was to assess whether
changes in tumor oxygenation occurred during ozone ther-
apy. Each patient served as his own control and elective non-
ozonated autohemotransfusion was not performed in a sepa-
rate control group. It was not considered ethical for these
advanced cancer patients to undergo invasive study-manipu-
lations over several days in a control group which, theoreti-
cally, did not offer any potential benefit (transfusion of
oxygenated blood is not a therapeutical approach). On the
other hand, several studies have already demonstrated that
the administration of ozone-free oxygen in a control group
does not produce the ‘prooxidant/antioxidant’ response
necessary to mediate the clinical effects of ozone therapy.
This reaction was produced only when ozone was added to
oxygen in equimolar amounts (18, 24 and 26).
In the course of ozone therapy by autohemotransfusion,
ozone, per se, does not enter the organism, and its effects are
mediated by rapid (a matter of seconds) oxidation of blood
components in the transfusion recipient. The oxidized mole-
cules and the specific antioxidant generated would vary
according to the levels of ozone therapy. The vascular effect
of ozonated blood transfusion is explained by an increase of
malonyldialdehyde and lipid peroxidation leading to leading
to activation of the hexose monophosphate shunt with an
increased production of 2,3-diphosphoglycerate in erythro-
cytes (27). This results in a displacement of the oxyhemo-
globin dissociation curve to the right and an increase in the
release of oxygen to the tissues. A pH decrease in erythro-
cytes may also shift the oxyhemoglobin dissociation curve to
the right (Bohr effect) without modification of 2,3-diphos-
phoglycerate (28). Furthermore, a charge modification in red
cell membranes results in an improvement in membrane
flexibility and a decrease in blood viscosity and resistance
(18,29). Adenosine, prostaglandins and, especially, nitric
oxide release could collaborate in affecting the micro-circula-
tion and lead to a decrease in vascular resistance (30).
Overall, ozone therapy decreased the percentage of values
≤10 and ≤5 mmHg at each measurement time-point. How-
Figure 3. Factor of change of pO2 (∆pO2) segregated with respect to the ini-
tial median pO2. The figure shows the ∆pO2 at each measurement time-point
following ozone therapy and segregated with respect to baseline pO2 value
above or below the median pO2 value (17 mmHg) of the overall study group.
The boxes show the 25%–75% inter-quartile interval, which includes the
50% values. The horizontal lines in the boxes represent the median and the
* represents the mean of ∆pO2 for both groups of tumors at each measure-
ment time-point. During ozone therapy, well-oxygenated tumors (baseline
pO2 above the median) showed no change (∆pO2 approximately 1) or even
decrease after session #3 (∆pO2 = 0.8). However the most ‘poorly-oxygen-
ated’ tumors (baseline pO2 below the median) showed increase in tumor
oxygenation (∆pO2 >1). These differences were significant at all the three
measurement time-points (P = 0.002, 0.001 and 0.002, respectively).
< Median = tumors with baseline pO2 values below the median value;
> Median = tumors with baseline pO2 values above the median value.
Figure 4. Factor of change of pO2 (∆pO2) after session #3 and hemoglobin
levels. There was an inverse and non-linear correlation between hemoglobin
levels and the ∆pO2 at each measurement time-point following ozone
therapy, i.e., a lower effect of ozone therapy was observed in patients with
higher hemoglobin levels. The figure shows the correlation with the ∆pO2
after session #3 (rho = –0.579, P = 0.019).eCAM 2004;1(1) 97
ever, no increase was observed in tumor pO2, as has been
reported in an animal study (31). In the present study, the
oxygenation decreased in tumors with pO2 concentrations
above the median. Based on the oxygen radio-sensitivity
curve, it can be inferred that this is not of clinical relevance in
well-oxygenated tumors. However, in tumors with baseline
pO2 below the median, i.e. tumors in which the radio-resist-
ance could increase in relation to this ‘adverse’ value, ozone
therapy actually increased the tumor pO2. This effect is simi-
lar to that observed by us (19) in anterior tibialis muscle
tissues following the administration of ozone therapy.
The mechanisms underlying this effect in tumors have yet
to be defined. Based on previously described effects, we
hypothesize that the inverse correlation between initial oxy-
genation and ∆pO2 in tumors and tissues during ozone ther-
apy is secondary to blood flow redistribution, i.e., a drop in
blood flow in well-oxygenated tissues in favor of less well-
oxygenated tissues. Tumor vessels have structural and func-
tional abnormalities with decreased or absent auto-regula-
tory mechanisms (32). Hence, an improvement in blood
rheologic parameters, as described by other authors (18,29),
could play an important role in the effect of ozone therapy in
high-resistance systems such as in tumors; this could apply to
at least the areas of the tumor that are most hypoxic. Con-
gruent with this concept is the improvement we observed with
ozone therapy in patients with lower hemoglobin levels and,
as a consequence, with lower blood viscosity. This vascular
effect is further supported by our preliminary studies with
Doppler techniques, indicating a lasting blood flow increase
following three alternating ozone therapy sessions (B. Clavo,
personal communication). However, our hypothesis of an
increase in tumor perfusion resulting from ozone therapy
needs further confirmation with studies specifically address-
ing the effect on tumor blood flow using, for example, multi-
channel laser Doppler.
Techniques such as hyperbaric chambers or carbogen
breathing plus nicotinamide can increase arterial pO2, with
secondary tumor pO2 increase. Usually, however, this is less
effective in modifying hypoxic areas and, as well, the effect is
of a very short duration; of the order of 10–15 minutes (33).
Furthermore, if applied for more than 15–30 min, these ther-
apies can lead to vaso-constriction resulting in a potential
blood-flow decrease, secondary to hyperoxia, in most organs
(34) as well as in tumors (33). Our results show that, in the
most hypoxic tumors, ozone therapy leads to an improve-
ment in tissue pO2 for at least 48 h after the second session of
therapy. Similarly, it should be noted that the hypoxic frac-
tion was decreased for protracted periods. Nevertheless,
better results could probably be achieved using combined
therapies, principally, techniques to increase blood oxygena-
tion.
On the other hand, metastatic or large-size tumors are
probably not the best situations in which to evaluate oxygen
delivery or the vascular effect of ozone therapy, as observed
in anemia-modification studies (35). However, for the pur-
pose of the present study, the patients selected were those
with advanced cancer or with large affected nodes that were
easily accessible to physical examination so as to facilitate the
tumor pO2 measurements.
Tumor hypoxia predisposes to a physiologic selection of
tumor cells with decreased apoptotic potential, which results
in resistance to radiotherapy and chemotherapy (2), higher
angiogenesis and a more aggressive tumor potential (3–5). If
ozone therapy successfully decreases tumor hypoxia in some
patients, it could be useful as an adjuvant in the treatment of
these patients by improving tumor oxygenation, by reducing
radio-resistance and improving local control. Survival could
be improved by decreasing tumor hypoxia, as shown by
Overgaard’s meta-analyses (15). The results of the present
study indicate that tumor pO2 modification could support
the anecdotal clinical reports of an improved effect of radio-
therapy in advanced tumors when ozone therapy is included
in the schedule (36).
Radio-mimetic (37) and synergistic (38) effects of radio-
therapy as well as growth inhibition of human cancer
cells by ozone (39) and increase in chemo-sensitivity in colon
carcinoma cells resistant to 5-fluorouracil (40) have been
described; albeit, these effects of ozone are not directly appli-
cable to human ozone therapy. However, from a clinical
oncology point of view, further research needs to be con-
ducted on the effects of ozone-enriched blood. The effects
described in relation to increasing antioxidant (22–26) and
cytokine production (41,42) are particularly relevant. A
review on the potential role of ozone therapy as a biological
response modifier in oncology has been published by Bocci
(43), and we concur with the view that the appropriate con-
trolled clinical trials would be particularly valuable.
In conclusion, many aspects regarding the bio-medical
application of ozone therapy remain unexplored. In the
present prospective study, the effect of ozone therapy on
human tumor pO2 has been measured using the polaro-
graphic probe technique, and the results indicate that ozone
therapy could increase oxygenation in the most hypoxic
tumors. This suggests the potential use of this therapy as
adjuvant in chemo-radiotherapy schedules, and would
warrant further investigation.
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